Antibodies are among the most versatile tools in modern biomedical research. They have helped propel advancements in study, characterization and diagnosis. They identify illnesses with unmatched accuracy and provide precise treatments.

However, custom monoclonal antibodies in biomedical research antibodies to target your specific needs can be a challenging and lengthy process. Antibody production requires a comprehensive understanding of key stages, including antigen design, immunization, hybridoma cell generation or recombinant antibody expression systems, protein production, purification methods and characterization. The Antibody and BioResource (ABR) Core focuses on two of the most critical tools central to rigorous and reproducible biomedical research: monoclonal antibodies (mAbs).

To create an antibody against a particular antigen, scientists first isolate B-lymphocytes from a mouse or rabbit and then amplify their VH and VL segments. The amplified segments are inserted into a vector, such as a phage display vector, that is infected with E. coli and then used to select clones that bind to the target antigen. The selected clones are then preserved for further characterization.

Once an antibody is produced, it must be purified using techniques such as ion exchange or size exclusion chromatography to remove any other antibodies that may interfere with its function. Characterization assays such as neutralization, flow cytometry and immunoprecipitation help determine the antibody’s binding affinity, specificity, and stability under various storage conditions.

Unlike traditional methods of antibody generation that involve animal immunization, recombinant production uses mammalian cells to produce the antibody in a high-yield system. This allows for the use of humanized antibodies that minimize the likelihood of an immune response and contributes to a broader trend in biotechnology to decrease dependence on animal-derived products.